Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078558013> ?p ?o ?g. }
- W2078558013 endingPage "423" @default.
- W2078558013 startingPage "415" @default.
- W2078558013 abstract "Coagulation activation appears to play a role in tumor progression. Low-molecular-weight heparin (LMWH) may influence tumor growth and LMWHs have been shown to beneficially influence tumor response to chemotherapy. In a phase II study using docetaxel plus enoxaparin in 25 patients with advanced breast cancer, fibrin monomer, transforming growth factor-beta 1 (TGF-β1) and response rates were evaluated. Enoxaparin was administered at a daily dose of 0, 5 or 1.0 mg/kg and docetaxel at 35–45 mg/m2 once weekly. Nine patients achieved a partial response (36%) and nine patients (36%) had stable disease. The median time to progression was 11.5 weeks (range 5–51 weeks), and 16 weeks combining patients with partial remission and stable disease. One major bleed occurred. Patients with partial remission had a significant decrease of TGF-β1 and fibrin (P < 0.05). A significant correlation between TGF-β1 and fibrin monomer was also seen in all subgroups independent of clinical response. The most frequent toxicities were granulocytopenia, asthenia, transient peripheral edema and temporary hot flushes. In conclusion, docetaxel plus enoxaparin was quite active and well tolerated in patients with advanced breast cancer. These preliminary data suggest further clinical research using chemotherapy plus enoxaparin as an antitumor therapy in advanced breast cancer is warranted." @default.
- W2078558013 created "2016-06-24" @default.
- W2078558013 creator A5001761071 @default.
- W2078558013 creator A5013259060 @default.
- W2078558013 creator A5020154189 @default.
- W2078558013 creator A5032114353 @default.
- W2078558013 creator A5061698687 @default.
- W2078558013 date "2007-07-01" @default.
- W2078558013 modified "2023-10-16" @default.
- W2078558013 title "Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study" @default.
- W2078558013 cites W115249879 @default.
- W2078558013 cites W1565561072 @default.
- W2078558013 cites W1760955494 @default.
- W2078558013 cites W1920767646 @default.
- W2078558013 cites W1920828316 @default.
- W2078558013 cites W1965288495 @default.
- W2078558013 cites W1966756337 @default.
- W2078558013 cites W1974571648 @default.
- W2078558013 cites W1976128207 @default.
- W2078558013 cites W1980067627 @default.
- W2078558013 cites W1987199100 @default.
- W2078558013 cites W1996544895 @default.
- W2078558013 cites W1997001753 @default.
- W2078558013 cites W2012424656 @default.
- W2078558013 cites W2015571839 @default.
- W2078558013 cites W2025176279 @default.
- W2078558013 cites W2028222320 @default.
- W2078558013 cites W2030590964 @default.
- W2078558013 cites W2033724005 @default.
- W2078558013 cites W2041154504 @default.
- W2078558013 cites W2043374008 @default.
- W2078558013 cites W2052492883 @default.
- W2078558013 cites W2060655128 @default.
- W2078558013 cites W2062262181 @default.
- W2078558013 cites W2080496987 @default.
- W2078558013 cites W2096497763 @default.
- W2078558013 cites W2111897685 @default.
- W2078558013 cites W2142386661 @default.
- W2078558013 cites W2150238019 @default.
- W2078558013 cites W2160638301 @default.
- W2078558013 cites W2167805334 @default.
- W2078558013 cites W2169521037 @default.
- W2078558013 cites W2179522519 @default.
- W2078558013 cites W2197375803 @default.
- W2078558013 cites W2312296163 @default.
- W2078558013 cites W2329311416 @default.
- W2078558013 cites W2338618131 @default.
- W2078558013 cites W2399822732 @default.
- W2078558013 cites W4299883346 @default.
- W2078558013 doi "https://doi.org/10.1097/mbc.0b013e3281139c1d" @default.
- W2078558013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17581315" @default.
- W2078558013 hasPublicationYear "2007" @default.
- W2078558013 type Work @default.
- W2078558013 sameAs 2078558013 @default.
- W2078558013 citedByCount "11" @default.
- W2078558013 countsByYear W20785580132013 @default.
- W2078558013 countsByYear W20785580132017 @default.
- W2078558013 countsByYear W20785580132018 @default.
- W2078558013 countsByYear W20785580132020 @default.
- W2078558013 countsByYear W20785580132021 @default.
- W2078558013 countsByYear W20785580132022 @default.
- W2078558013 crossrefType "journal-article" @default.
- W2078558013 hasAuthorship W2078558013A5001761071 @default.
- W2078558013 hasAuthorship W2078558013A5013259060 @default.
- W2078558013 hasAuthorship W2078558013A5020154189 @default.
- W2078558013 hasAuthorship W2078558013A5032114353 @default.
- W2078558013 hasAuthorship W2078558013A5061698687 @default.
- W2078558013 hasConcept C121608353 @default.
- W2078558013 hasConcept C126322002 @default.
- W2078558013 hasConcept C143998085 @default.
- W2078558013 hasConcept C203014093 @default.
- W2078558013 hasConcept C2775930923 @default.
- W2078558013 hasConcept C2776694085 @default.
- W2078558013 hasConcept C2776884760 @default.
- W2078558013 hasConcept C2777557582 @default.
- W2078558013 hasConcept C2778822529 @default.
- W2078558013 hasConcept C2781190966 @default.
- W2078558013 hasConcept C31760486 @default.
- W2078558013 hasConcept C530470458 @default.
- W2078558013 hasConcept C54173615 @default.
- W2078558013 hasConcept C71924100 @default.
- W2078558013 hasConcept C90924648 @default.
- W2078558013 hasConceptScore W2078558013C121608353 @default.
- W2078558013 hasConceptScore W2078558013C126322002 @default.
- W2078558013 hasConceptScore W2078558013C143998085 @default.
- W2078558013 hasConceptScore W2078558013C203014093 @default.
- W2078558013 hasConceptScore W2078558013C2775930923 @default.
- W2078558013 hasConceptScore W2078558013C2776694085 @default.
- W2078558013 hasConceptScore W2078558013C2776884760 @default.
- W2078558013 hasConceptScore W2078558013C2777557582 @default.
- W2078558013 hasConceptScore W2078558013C2778822529 @default.
- W2078558013 hasConceptScore W2078558013C2781190966 @default.
- W2078558013 hasConceptScore W2078558013C31760486 @default.
- W2078558013 hasConceptScore W2078558013C530470458 @default.
- W2078558013 hasConceptScore W2078558013C54173615 @default.
- W2078558013 hasConceptScore W2078558013C71924100 @default.
- W2078558013 hasConceptScore W2078558013C90924648 @default.
- W2078558013 hasIssue "5" @default.